

ADVANCES IN BIOTECHNOLOGICAL PROCESSES

VOLUME 6

Editor
Avshalom Mizrahi

Alan R. Liss, Inc., New York

ADVANCES IN BIOTECHNOLOGICAL PROCESSES

Volume 6

Editor

Avshalom Mizrahi

**Israel Institute for Biological Research
Ness Ziona, Israel**

ALAN R. LISS, INC., NEW YORK

Address all Inquiries to the Publisher
Alan R. Liss, Inc., 41 East 11th Street, New York, NY 10003

Copyright © 1986 Alan R. Liss, Inc.
Printed in the United States of America

Under the conditions stated below the owner of copyright for this book hereby grants permission to users to make photocopy reproductions of any part or all of its contents for personal or internal organizational use, or for personal or internal use of specific clients. This consent is given on the condition that the copier pay the stated per-copy fee through the Copyright Clearance Center, Incorporated, 27 Congress Street, Salem MA 01970, as listed in the most current issue of "Permissions to Photocopy" (Publisher's Fee List, distributed by CCC, Inc.) for copying beyond that permitted by sections 107 or 108 of the US copyright law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

ISSN 0736-2293
ISBN 0-8451-3205-9

ADVANCES IN BIOTECHNOLOGICAL PROCESSES

Volume 6

Editor

Avraham Mizrahi

Israel Institute for Biological Research

Beer-Sheva, Israel

DEK, INC., NEW YORK, N.Y. NEW YORK

Contributors

Hans Bender, Lehrstuhl für Organische Chemie und Biochemie der Universität Freiburg i.Br., Federal Republic of Germany [31]

Michael Epstein, Tayco Diagnostics Ltd., Ramat Gan 52523, Israel [179, 219]

Nava Epstein, Department of Microbiology, Israel Institute for Biological Research, Ness Ziona 70450, Israel [179, 219]

Claude Gudin, Association pour la Recherche en Bioénergie Solaire, CEN - Cadarache, 13108 Saint Paul lez Durance Cedex, France [73]

Eitan Israeli, Department of Virology, Israel Institute for Biological Research, Ness Ziona 70450, Israel [1]

David Kobiler, Department of Microbiology, Israel Institute for Biological Research, Ness Ziona 70450, Israel [219]

Otto-Wilhelm Merten, Sandoz Forschungsinstitut Gesellschaft m.b.H., A-1235 Vienna, Austria; present address: Institut Pasteur, 28 rue du Docteur Roux, F-75724 Paris, France [111]

Avshalom Mizrahi, Israel Institute for Biological Research, Ness Ziona 70450, Israel [xiii]

Gerhard Ernst Palfi, Sandoz Forschungsinstitut Gesellschaft m.b.H., A-1235 Vienna, Austria [111]

D.J. Rowlands, Wellcome Biotechnology Ltd., Foot and Mouth Disease Division, Woking, Surrey GU24 0NQ, England [253]

Johannes Steiner, Sandoz Forschungsinstitut Gesellschaft m.b.H., A-1235 Vienna, Austria [111]

Catherine Thepenier, Association pour la Recherche en Bioénergie Solaire, CEN - Cadarache, 13108 Saint Paul lez Durance Cedex, France [73]

The number in brackets is the opening page number of the contributor's article.

Preface

This, the sixth volume in the series **Advances in Biotechnological Processes**, covers in depth several important and interesting aspects of the production and manufacture of biologicals.

For the first time, the topic of biosafety in experimental and commercial production of biologicals is covered in detail. This contribution was intended to fill a gap in the literature, particularly with regard to safety applications in R&D relating to infectious agents and genetic engineering hazards. Also included is a risk assessment that considers the agent, the worker, and the process. Another topic covered in detail is the subject of cyclodextrin manufacture by microbial digestion. This chapter deals with the biochemistry of cyclodextrin glycosyltransferases, including their isolation and purification, as well as their degradation, production, and modification. The applications of the cyclodextrin inclusion complexes are described fully, with special reference to their enhancement properties.

Solar energy applications have also found a role in biotechnology. Through the bioconversion of solar energy into microalgae, it is possible to create polysaccharides, lipids, hydrocarbons, pigments, and antibiotics, among other pharmaceuticals.

On-line instrumentation for determining biochemical and physiologic parameters that govern the fermentation of animal cells permits refined applications of biosensors in the determination of various enzymes and their levels of production, a topic that is covered in the third chapter of this volume.

Hybridoma technology in the production of human monoclonal antibodies and lymphokines is also described fully. From preparation of parent cells, through fusion techniques, to large-scale production and long-term storage, this technology has broad applications in the 1980s and beyond.

The last of the seven chapters in this volume of **Advances in Biotechnological Processes** describes in detail the problems associated with the handling of synthetic viral vaccines, particularly those that are genetically engineered.

It is to be hoped that the comprehensive treatment of these aspects of creating and producing biologicals will be of value to laboratory scientists in industry and in the university, as well as to postgraduate students and others interested in this burgeoning field of scientific growth—a field that has widespread applications in the pharmaceutical and health sciences, agriculture, nutrition, pollution control, and energy conservation.

Avshalom Mizrahi

Contents of Previous Volumes

Volume 1

Bioreactors for Submerged Culture, Daniel N. Bull, Richard W. Thoma, and Thomas E. Stinnett

Affinity Chromatography: Its Application to Industrial Scale Processes, Elizabeth A. Hill and Michael D. Hirtenstein

Airlift Fermenters: Construction, Behavior, and Uses, U. Onken and P. Weiland

Concepts on the Biotransformation of Carbohydrates Into Fuel Ethanol, Carlos Rolz, Sheryl de Cabrera, Francisco Calzada, Ricardo García, Roberto de León, María del Carmen de Arriola, Fabiola de Micheo, and Edna Morales

Methane Production by Fermentation of Agricultural Residues, Edgar G. Clausen and James L. Gaddy

Microbial Utilization of Methanol: Production of Useful Metabolites, Nobuo Kato, Yoshiki Tani, and Hideaki Yamada

Immobilized Cells in Preparation of Fine Chemicals, Ichiro Chibata, Tetsuya Tosa, and Tadashi Sato

Microbial Extraction and Concentration of Metals, Donald G. Lundgren and E. Edward Malouf

The New β -Lactam Antibiotics, D. Butterworth, J.D. Hood, and M.S. Verrall

Single-Cell Protein Production: Review of Alternatives, Nissim S. Samuelov

Volume 2

Microcarriers for Culturing Mammalian Cells and Their Applications, Shaul Reuveny

Production of Veterinary Vaccines, Raymond E. Spier

Production of Enzymes and Hormones by Mammalian Cell Culture, H.W.D. Katinger and R. Bliem

Large-Scale Production of Extrinsic (Tissue-Type) Plasminogen Activator From Human Melanoma Cells, C. Kluft, A.L. van Wezel, C.A.M. van der Velden, J.J. Emeis, J.H. Verheijen, and G. Wijngaards

Interleukin-2 and Interleukin-3: Suspension Cultures of Constitutive Producer Cell Lines, F. Klein, R. Ricketts, D. Pickle, and M.C. Flickinger
Chemicals From Plant Cell Fermentation, Michael W. Fowler and Gagik Stepan-Sarkissian
Production of Human Fibroblast Interferon in the Presence or Absence of Fetal Bovine Serum, Robert Dennin, Carol Kramer, Sandra Evans, and Michael J. Kramer
Production and Concentration of Interferon From Human Leukocytes, Philip C. Familletti
Interferon Production by Human Lymphoblastoid Cells, Arye Lazar
Production of Human Immune Interferon, Jacob Shoham
Automated Immunosorbent Purification of Interferon, S. Joseph Tarnowski and R.A. Liptak, Jr.

Volume 3

Fermenter Instrumentation and Control, Stephen W. Carleysmith and Richard I. Fox
Industrial Application of Fermentation Kinetics, Tsunetomo Asai and Takehiko Kono
The Preservation of Genetically Unstable Microorganisms and the Cryopreservation of Fermentation Seed Cultures, R.J. Sharp
Antibody-Toxin Conjugates: A New Approach to Cancer Therapy, Deirdre P. McIntosh
Production of Daunorubicin, Ronald Michael Stroshane
Recent Developments in the Process Improvement of Production of Antitumor Anthracycline Antibiotics, Toshikazu Oki
The Fermentative Production of Ergot Alkaloids, James Earl Robbers
Microbial Desulfurization of Coal, Fikret Kargi
Bioinsecticides: I. *Bacillus thuringiensis*, Aloysius Krieg and Herbert G. Miltenburger
Bioinsecticides: II. *Baculoviridae*, Herbert G. Miltenburger and Aloysius Krieg
***Bacillus sphaericus*: Microbiological Factors Related to Its Potential as a Mosquito Larvicide**, Allan A. Yousten

Volume 4

Genetic Engineering of Human Interferons From Lymphoblastoid Cells: I. Cloning of Interferon Species Expressed in Sendai-Induced Namalva Cells, Sara Cohen, Baruch Velan, and Avigdor Shafferman
Genetic Engineering of Human Interferons From Lymphoblastoid Cells: II. Construction of *trp* Expression Plasmids and Their Use for Efficient Expression of IFN- α J1, Avigdor Shafferman, Sara Cohen, Haim Grosfeld, Moshe Leitner, and Baruch Velan

Genetic Engineering of Human Interferons From Lymphoblastoid Cells: III. Purification, Physicochemical and Biological Properties of Bacterial IFN- α J1, Haim Grosfeld, Sara Cohen, Baruch Velan, and Avigdor Shafferman

Electrofusion: A Novel Hybridization Technique, U. Zimmermann, J. Vienken, J. Halfmann, and C.C. Emeis

Production, Characterization, and Clinical Utility of Carcinoembryonic Antigen, Wing Kam, Dean Tsao, Steven H. Itzkowitz, and Young S. Kim

Microbial Conversion of Sulfate to Sulfur—An Alternative to Gypsum Synthesis, Douglas J. Cork

Flocculating Agents of Microbial Origin, Christopher F. Forster, Nicholas J.B. Knight, and D.A. John Wase

Secondary Metabolites From Plant Cell Suspension Cultures: Methods for Yield Improvement, J.S. Rokem and I. Goldberg

Blood Fractionation: Proteins, Martin H. Stryker, Maurice J. Bertolini, and Yu-lee Hao

Volume 5

Culture Media for Propagation of Mammalian Cells, Viruses, and Other Biologicals, David W. Jayme and Kenneth E. Blackman

Protein Modeling Using Computer Graphics, A.J. Morffew

New Trends in Lignin Biodegradation, Matti S.A. Leisola and Armin Fiechter

Plant Tissue Culture Technology and Crop Improvement, M.G.K. Jones and A. Karp

Production of Poultry Viral Vaccines in Embryonated Eggs, David Ben-Nathan

Biodegradation in Effluents, Rufus K. Guthrie and Ernst M. Davis

The Rotating Biological Contactor for Wastewater Treatment, Peter F. Strom and Jae-Chun Chung

Mushroom Fermentation, Thomas E. Tautorius

Production of Plasminogen Activator by Cells in Culture, A. Kadouri and Z. Bohak

Contents

Contributors	x i
Preface	
<i>Avshalom Mizrahi</i>	xiii
Contents of Previous Volumes	xv
Biosafety in Biotechnological Processes	
<i>Eitan Israeli</i>	
I. Introduction	2
II. Occurrence and Severity of Laboratory Infections	3
III. Sources and Causes of Infections in Biotechnological Laboratories	4
A. Accidents in the Laboratory	4
B. Aerosol-Producing Processes	5
C. Human Factors	6
D. Laboratory Animals	7
IV. Assessment of the Risks in Biotechnological Processes	7
A. The Agent	8
B. The Worker	8
C. The Process	9
D. Scaling-Up Biotechnological Processes	9
V. Hazards in Biotechnological Processes	11
A. Cell Cultures, Oncogenic Viruses, and Hybridomas	11
B. Slow Viruses	12
C. Vaccine Production	13
D. Blood Products	14
E. Genetic Engineering Hazards	14
F. The Environment Connection	15
VI. Making Biotechnological Processes Safer	16
A. Safety Education, Procedures, and Practices	16
1. Education	16
2. Good Laboratory Practice (GLP)	17
3. Good Manufacturing Practices (GMP)	17
4. Code of Practice (COP)	17
B. Physical Containment	18
C. Safety Equipment	18
D. Biological Containment	25
E. Automation and Computer Control	26
VII. Conclusion	26
VIII. References	27

vi ◇ Contents

Production, Characterization, and Application of Cyclodextrins

Hans Bender

I. Introduction	32
II. Cyclodextrin Glycosyltransferases	33
A. Properties of CGTs	33
B. Assays for CGT Activity	34
C. Production of CGTs	35
D. Isolation and Purification of CGTs	36
1. Purification of the CGT From the Alkalophilic <i>Bacillus</i> 38-2	37
2. Purification of the CGT From <i>Bacillus macerans</i>	37
E. Immobilized CGTs	39
III. Cyclodextrins	39
A. Molecular Characteristics of CDs	39
B. Degradation of CDs	40
1. Acid Hydrolysis, Gamma Radiolysis	41
2. Enzymic Degradation of CDs	41
C. Inhibition of Enzymes by CDs	42
D. Toxicology of CDs	42
E. Analysis of CDs	42
F. Production of CDs	43
1. General Aspects	43
2. Examples of Production and Purification of CDs	45
a. Preparation of cG ₆	45
b. Preparation of cG ₇	46
c. Preparation of cG ₈	48
d. Preparation of Branched CDs	51
IV. Modification of CDs	51
A. Monomeric CD Derivatives	51
B. CD Polymers	55
1. Cross-Linked CDs	55
2. Matrix-Coupled CDs	55
V. Application of CDs	56
A. CD-Inclusion Complexes	56
B. Preparation of CD-Inclusion Complexes	56
C. Resolution of Enantiomers	59
VI. Catalytical Properties of CDs	59
VII. CDs as Models for Enzymes	61
VIII. References	61

Bioconversion of Solar Energy Into Organic Chemicals by Microalgae

Claude Guadin and Catherine Thepenier

I. Introduction	74
II. Potential of Microalgae and Cyanobacteria as Organic Chemical Producers	74
A. Polysaccharides	75
B. Lipids and Hydrocarbons	75
C. Osmoregulating Products in Cells of Microalgae and Cyanobacteria	78
D. Pigments	78
E. Antibiotics, Antifungal Agents, and Toxin Compounds	78
III. Microalgae Mass Culture Technology	80
A. Historical Review	80

B. General Considerations	82
C. The Tubular Photobioreactor	83
D. Technology in Relation to Biological Efficiencies	87
1. Temperature Control	87
2. Materials	87
3. CO ₂ Transfer	91
4. Pumping	91
E. Harvesting	92
IV. Production of Organic Chemicals by Immobilized Microalgae	94
A. Immobilization Methods and Support Materials	95
B. Historical Review	96
C. Photobioreactor for Organic Chemical Production	97
1. Hydrocarbon Production From <i>Botryococcus braunii</i>	97
2. Glycerol Production From <i>Dunaliella parva</i>	97
3. Sulfated Polysaccharide Production From <i>Porphyridium cruentum</i>	98
V. Conclusion	102
VI. References	104

On-Line Determination of Biochemical/Physiological Parameters in the Fermentation of Animal Cells in a Continuous or Discontinuous Mode

Otto-Wilhelm Merten, Gerhard Ernst Palfi, and Johannes Steiner

I. Introduction	112
II. Sensor Applications and Sampling Devices	112
III. Biosensor Transducers	119
A. Potentiometric Devices	120
B. Amperometric Devices	122
C. Optical Biosensors, Optoelectronic Devices	124
D. Calorimetric Devices	124
E. Conductimetric Devices	124
F. Piezoelectric Crystals	125
G. Problems Developing With the Application of Biosensors in a Bioreactor	125
IV. Calibration: Influence of the Sample Matrix	125
V. Principles and Special Applications of Sensors	130
A. Determination of the Biomass	130
B. Determination of Nutrients and Metabolites	132
1. Determination of Glucose Concentrations	144
2. Determination of Lactate and Pyruvate Concentrations in Supernatants	153
3. Determination of Ammonia Concentration in Supernatants	156
4. Determination of Amino Acids	156
C. Determination of the Product Concentration in Animal Cell Culture Supernatants	165
VI. Conclusions	171
VII. References	171

The Hybridoma Technology: I. Production of Monoclonal Antibodies

Nava Epstein and Michael Epstein

I. Introduction	180
II. Background	181
A. Diverse Potential of Antibodies	181
B. Structure of the Antibody Molecule	182

viii ◇ Contents

C. Insufficiency of Polyclonal Antisera	182
D. Sources of Homogeneous Antibodies	184
III. Hybridoma Technology	185
A. Introduction and Principles	185
B. Immunization Procedures	188
C. Choice of Myelomas	189
D. Maintenance of Myeloma Cell Lines	190
E. Media and Solutions for Cell Fusion	190
F. Preparation of Parental Cells	193
1. Spleen Cells	193
2. Myeloma Cells	193
G. Fusion Techniques	193
1. PEG Method	193
2. Electrofusion Technique	195
H. Cloning of Hybrid Cells	196
1. Limiting Dilution Method	196
2. Soft Agar Method	197
I. Production of Human Monoclonal Antibodies	197
1. Immunization and Cell Sources	198
2. Cell Preparation Procedure	198
3. Human Parental Cell Lines	198
J. Methods for Determination of Activity and Specificity of Monoclonal Antibodies	199
1. Binding Assays	200
2. Assays Based on Biological Activity	202
3. Hemagglutination Assays	203
4. Cytolytic Assays	204
5. Direct Detection of Antibody-Secreting Cells	204
6. Determination of Class and Subclass of Antibodies	205
K. Isolation and Characterization of Antigens From Complex Mixtures by Monoclonal Antibodies	206
L. Long-Term Storage of Hybridoma Cells	206
1. Freezing Procedure	206
2. Thawing Procedure	207
M. Mycoplasma in Hybridoma Cultures	207
N. Large-Scale Production of Monoclonal Antibodies	207
1. In Vivo Production of Ascites Tumors	207
2. In Vitro Production of Monoclonal Antibodies	208
O. Purification of Monoclonal Antibodies	209
P. Storage and Stability of Monoclonal Antibodies	209
IV. References	210

The Hybridoma Technology: II. Applications of Hybrid Cell Products: Monoclonal Antibodies and Lymphokines

Nava Epstein, David Kobiler, and Michael Epstein

I. Introduction	220
II. Surface Antigens of Animal Cells	221
A. Tumor Markers	221
B. T-Cell Subsets	226
C. The Human Lymphocytic Antigen System (HLA)	227
III. Infectious Pathogens	228

A. Monoclonal Antibodies in Passive Immunization	228
B. Vaccine Preparation	229
C. Parasite Antigens	230
1. Immunodiagnostic Assays	230
2. Differentiation	231
3. Purification	231
4. Anti-Parasite Action	231
D. Viral Antigens	231
IV. Enzymes and Other Proteins	232
V. Hormones, Drugs, and Their Receptors	233
VI. Immunoglobulins and the Immune Response	235
VII. The Pros and Cons of Monoclonal Antibodies	237
A. Commercialization	237
1. Properties	237
2. Production	238
B. Application/Potential	238
1. Immunodiagnosis	238
2. Human Imaging	238
3. Target Therapy	239
4. Biochemical Preparation	239
5. Human McAbs	239
VIII. T-Cell Hybridomas Secreting Lymphokines	239
IX. References	241

New Advances in Animal and Human Virus Vaccines

D. J. Rowlands

I. Introduction	254
II. Problems Associated With Current Vaccines	255
A. Diseases for Which No Vaccine Is Available	255
B. Live Attenuated Vaccines	256
C. Inactivated Vaccines	257
D. Antigenic Variation	259
III. Expression of Viral Antigens in Prokaryotes	260
IV. Expression of Viral Antigens in Eukaryotes	264
V. Modified Live Virus Vectors	265
VI. Synthetic Peptide Antigens	268
A. Choice of Peptide Sequence	269
1. Antigenic Activity of Protein Fragments	269
2. Regions of Sequence Hypervariability	270
3. Sequence Changes Selected by Monoclonal Antibodies	270
4. Prediction From Secondary Structure Considerations	271
5. Analysis of Antibody Reactions With Overlapping Sets of Peptides	272
B. Peptide Conformation	273
C. Induction of Antibodies to Immunorecessive Sites	274
VII. Antidiotype Vaccines	276
VIII. Attenuation by Direct Gene Manipulation	277
IX. Antigen Presentation and Adjuvants	278
X. Conclusion	279
XI. References	281

Index	287
------------------------	------------

Biosafety in Biotechnological Processes

Eitan Israeli

Department of Virology, Israel Institute for Biological Research,
Ness Ziona 70450, Israel



I. Introduction	2
II. Occurrence and Severity of Laboratory Infections	3
III. Sources and Causes of Infections in Biotechnological Laboratories	4
A. Accidents in the Laboratory	4
B. Aerosol-Producing Processes	5
C. Human Factors	6
D. Laboratory Animals	7
IV. Assessment of the Risks in Biotechnological Processes . . .	7
A. The Agent	8
B. The Worker	8
C. The Process	9
D. Scaling-Up Biotechnological Processes	9
V. Hazards in Biotechnological Processes	11
A. Cell Cultures, Oncogenic Viruses, and Hybridomas . . .	11
B. Slow Viruses	12
C. Vaccine Production	13
D. Blood Products	14
E. Genetic Engineering Hazards	14
F. The Environment Connection	15
VI. Making Biotechnological Processes Safer	16
A. Safety Education, Procedures, and Practices	16
1. Education	16
2. Good Laboratory Practice (GLP)	17
3. Good Manufacturing Practices (GMP)	17
4. Code of Practice (COP)	17
B. Physical Containment	18
C. Safety Equipment	18
D. Biological Containment	25
E. Automation and Computer Control	26
VII. Conclusion	26



I. INTRODUCTION

The great Chinese philosopher Confucius asked: “What can you do if you have to confront a tiger?” He analyzed the alternatives and suggested three strategies: 1) you can put on heavy armor that the tiger cannot harm; 2) you can use suitable weapons to kill the tiger; 3) you can throw a cage over the tiger and lock him in.

What are the parallel concepts applied to biotechnology safety? Let us say that the various hazardous biological agents are the tiger. As for the armor—we can defend ourselves by safety equipment and regulations; the weapons used are decontamination methods and materials; and the cage is the safety cabinets that keep the hazardous agents away from the worker and the environment.

But let us ask ourselves: are biotechnological processes hazardous at all and do we have to be concerned about our safety? In the tiger case the danger is understood by everybody; it is not so obvious when we deal with routine laboratory experiments and techniques in research and development, and much less so in the vast variety of well-established and upscaled biotechnological processes.

Let us ask another question: do we have to be afraid of the big bad tiger, or shall we say the little bad virus? We all fear the unknown if we know that a danger exists and do not know how to handle it. This fear might lead to wrong decisions and faulty execution, which can result in accidents and infection. Conversely, overconfidence, negligence, or ignorance of the danger cause many accidents. That is why we have to be aware of the hazards and to learn how to minimize them by applying relevant safety rules, procedures, and equipment.

Another point to consider is the attitude toward biological safety. Some scientists tend to mitigate the hazards, bearing in mind only the execution of the experiment, and dismiss all safety demands. This attitude is wrong and inconceivable today. The motto in the biological laboratory should be: “No experiment is so important that it can’t be done safely.” There is nothing heroic in getting infected in the lab; maybe it was in Pasteur’s day, but it is unacceptable today. Additionally, it is one thing to take a chance with your own health, as did Pasteur, but unsafe handling of hazardous biological agents can affect innocent bystanders and can have an unforeseen impact on the environment.

A special emphasis must be applied to safety in biotechnological processes; in addition to the usual hazards in the research and development